Barclays analyst Jack Meehan now sees a 35% chance (vs. 20% previously) that Myriad Genetics' (MYGN -7.9%) GeneSight test could lose out on Medicare coverage.
He trims his price target to $18 from $20. With today's decline, MYGN is trading just below $24. The average sell-side price target is roughly $35, and the average sell-side rating is Outperform.
Now read: Myriad Genetics: Buy, Sell Or Hold? »
Subscribe for full text news in your inbox